Catalyst Pharmaceuticals, Inc.

As of October 24, 2025, Catalyst Pharmaceuticals, Inc. shows a mildly bearish technical trend with mixed signals across timeframes, as the weekly MACD is mildly bullish while the monthly MACD and daily moving averages indicate bearish sentiment.

As of October 24, 2025, Catalyst Pharmaceuticals, Inc. shows a mildly bearish trend, with mixed signals from the MACD indicators and daily moving averages, despite a recent 2.00% weekly return that outperformed the S&P 500's 1.92%.

As of October 3, 2025, Catalyst Pharmaceuticals, Inc. shows a mildly bearish trend with mixed signals from technical indicators, having outperformed the S&P 500 in the past week but underperformed year-to-date.

As of October 3, 2025, Catalyst Pharmaceuticals, Inc. shows a mildly bearish trend with mixed technical indicators, having outperformed the S&P 500 recently but lagging behind on a year-to-date basis, suggesting caution despite short-term strength.

As of October 3, 2025, Catalyst Pharmaceuticals, Inc. shows a mildly bearish technical trend with mixed signals across indicators, having outperformed the S&P 500 in the short term but underperformed year-to-date and over the past year.

As of August 7, 2025, Catalyst Pharmaceuticals, Inc. has shifted to a bearish technical trend, with negative indicators across multiple metrics and underperformance compared to the S&P 500.

As of June 30, 2025, Catalyst Pharmaceuticals, Inc. is considered very attractive due to its undervalued status, evidenced by a P/E ratio of 17, a PEG ratio of 0.11, and a high ROCE of 108.10%, despite a recent year-to-date return of -2.25% compared to the S&P 500's 12.22%, while achieving a remarkable 507.14% return over the past five years.

As of February 26, 2025, Catalyst Pharmaceuticals, Inc. is rated very attractive due to its undervaluation, with a P/E ratio of 17 compared to the peer average of 28.13, a PEG ratio of 0.11, a competitive EV/EBITDA ratio of 9.56, and strong profitability metrics, while also outperforming the S&P 500 with a 41.89% return over the past year.

As of June 17, 2025, the trend is mildly bullish with daily moving averages supporting this view, but weekly indicators show mild bearishness, creating mixed signals across different time frames.

As of March 2022, the management team of Catalyst Pharmaceuticals, Inc. includes Patrick McEnany as Chairman, President, and CEO, with Charles O'Keeffe as Lead Independent Director and Richard Daly, Donald Denkhaus, and Dr. David Tierney as Independent Directors.

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapies for rare diseases. As of March 2025, it reported net sales of $141 million and a net profit of $57 million, with a market cap of approximately $2.83 billion.

As of Jun 18, Catalyst Pharmaceuticals, Inc. has a market capitalization of $2.83 billion, with net sales of $534.64 million and a net profit of $197.35 million over the last four quarters.